Nivolumab for Resected Stage III or IV Melanoma at 9 Years
The 9-year final data support a sustained finding of longer recurrence-free survival with nivolumab than with ipilimumab. (Funded by Bristol Myers Squibb and Ono Pharmaceutical; CheckMate 238 ClinicalTrials.gov number, NCT02388906; Eudra-CT number, 2014-002351-26.).
Authors
- Michele Del Vecchio (ORCID: https://orcid.org/0000-0001-9060-2512)
- Marcus O. Butler (ORCID: https://orcid.org/0000-0002-9840-7057)
- Ana Arance (ORCID: https://orcid.org/0000-0003-2896-1957)
- Luis de la Cruz‐Merino (ORCID: https://orcid.org/0000-0002-5333-0535)
- Andrew F. Hill (ORCID: https://orcid.org/0000-0001-5581-2354)
- Leslie A. Fecher (ORCID: https://orcid.org/0000-0002-6534-7457)
- Michael Schenker (ORCID: https://orcid.org/0000-0003-2645-6391)
- Devanand Joseph
- Paolo A. Ascierto (ORCID: https://orcid.org/0000-0002-8322-475X)
- Barbara Merelli
- Melanie Pe Benito
- Petr Arenberger (ORCID: https://orcid.org/0000-0002-4800-5877)
- Paul Craig Nathan (ORCID: https://orcid.org/0000-0003-0334-0871)
- Caroline Gaudy‐Marqueste (ORCID: https://orcid.org/0000-0001-6955-5117)
- Charles Lance Cowey (ORCID: https://orcid.org/0000-0002-9726-5309)
- Jacopo Pigozzo (ORCID: https://orcid.org/0000-0003-2427-8915)
- Nikhil I. Khushalani (ORCID: https://orcid.org/0000-0002-3636-4143)
- Iván Márquez‐Rodas (ORCID: https://orcid.org/0000-0002-2476-668X)
- Paola Queirolo (ORCID: https://orcid.org/0000-0002-9917-6633)
- Stéphane Dalle (ORCID: https://orcid.org/0000-0002-3423-4548)
- James Larkin (ORCID: https://orcid.org/0000-0001-5569-9523)
- Margarita Askelson (ORCID: https://orcid.org/0000-0001-9133-7693)
- Michael Millward (ORCID: https://orcid.org/0000-0002-1744-1617)
- Raheela Soomro
- Oleg Gligich
- Helen J Gogas (ORCID: https://orcid.org/0000-0002-0451-2885)
- Victoria Atkinson
- Anna Maria Di Giacomo
- Dhanrajsinh Rathod
Institutions
- University of Siena (IT)
- The University of Queensland (AU)
- The University of Western Australia (AU)
- National and Kapodistrian University of Athens (GR)
- Charles University (CZ)
- Aix-Marseille Université (FR)
- University of Michigan (US)
- Texas Oncology (US)
- Princess Alexandra Hospital (AU)
- Sir Charles Gairdner Hospital (AU)
- Princess Margaret Cancer Centre (CA)
- University of Medicine and Pharmacy of Craiova (RO)
- Hospital General Universitario Gregorio Marañón (ES)
- Moffitt Cancer Center (US)
- Assistance Publique Hôpitaux de Marseille (FR)
- Hospital Universitario Virgen Macarena (ES)
- Bristol-Myers Squibb (United States) (US)
- Hospices Civils de Lyon (FR)
- Ospedale Papa Giovanni XXIII (IT)
- Mount Vernon Cancer Centre (GB)
- Istituto Oncologico Veneto (IT)
- Trans Tasman Radiation Oncology Group (AU)
- Royal Marsden Hospital (GB)
- Gallipoli Medical Research Foundation (AU)
- Instituto de Biomedicina de Sevilla (ES)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- University Hospital Kralovske Vinohrady (CZ)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- European Institute of Oncology (IT)
- Universidad de Sevilla (ES)
- University of Craiova (RO)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-10-18
- DOI
- https://doi.org/10.1056/nejmoa2504966
- Citations
- 9
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 9.41